Efficacy of intravenous immunoglobulin in the treatment of a COVID-19 patient

Introduction. Diabetes mellitus patients are a vulnerable group of people who prone to getting infected with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). The has high binding affinity angiotensin-converting enzyme receptor, which allows efficient host cell entering, prolonged retention, and possibility insulin resistance ketoacidosis development. Case outline. We describe case 20-year-old patient past medical history type 1 diabetes presented bilateral COVID-19 pneumonia. Initially, treatment polyvitamin therapy, corticosteroids, tocilizumab, convalescent plasma did not improve the patient?s condition, but might have led worsening underlying disease, blood glucose level, ketoacidosis. Patient developed rapid progression disease pneumonia that required intubation mechanical ventilation. Intravenous immunoglobulin (IVIg) was administrated in order suppress hyperactive immune response through its immunomodulatory effect. Forty-eight hours later, gas exchange improved, almost complete regression changes lungs seen, normalization metabolic parameters detected. After 14 days hospitalization, discharged good general condition. Conclusion. complicated by leads poor outcome antiviral anti-inflammatory activity IVIg suggests it may be useful therapeutic agent cases COVID-19. In case, application improvement